Elaine's Fight for Sight
68-year-old Elaine, from South Lancashire in Scotland was diagnosed with wet age-related macular degeneration in 2016.
Now, Elaine is taking part in Fight for Sight’s ’20 Voices for 2020’ campaign, to encourage everyone to get regular eye exams.
Explaining how she came to be diagnosed with age-related macular degeneration, Elaine said: “I felt as if my eyes were dulling over a bit. I just thought I was tired because at that point I was still working. But when I went to get my eyes checked they could see something wasn’t right so they referred me to the hospital and that’s when I was diagnosed.”
Elaine started treatment for the condition straight away, which involves injections into the eye. A year and a half after her diagnosis, Elaine stopped driving because she was finding it too difficult to see, particularly at night.
She said: “The biggest impact my eye condition has had on my life is not being able to drive anymore. I live in the countryside, so when I need to go for my injections every few weeks, it’s a two hour bus journey to get to the clinic and a two hour bus journey home. In winter, that’s particularly difficult. I did feel my eye sight was improving though as a result of the treatment and I was pleased with the progress.”
Elaine says that research into age-related macular degeneration gives her hope.
She said: “I'm really hopeful that research will mean better treatments in the future for my condition. Anything which reduces the need for injections or their frequency would make such a difference to me and others, as the current treatment available really impacts my lifestyle. It could also mean better access to treatments and lead to less people needing to attend the hospital clinics, which would be a very positive thing for our NHS.”
The 20 Voices campaign is part of Fight for Sight’s wider 2020 campaign, which included the release of our major research study ‘Time to Focus’ showing the economic and personal impact of sight loss.Read the Time to Focus report Read more about our research into age-related macular degeneration
Share this page